FDA Accepts Supplement for Fluoxetine Hydrochloride by Sciegen Pharmaceuticals
The FDA has accepted a supplemental application for Fluoxetine Hydrochloride submitted by Sciegen Pharmaceuticals.
Therapeutic Area
Therapeutic area intelligence for Antidepressant with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.